Moleculin Biotech, Inc.

MBRX XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

15M

Short interest (Jul 15)

14.9%

Net Short (Jul 27 ): 0.0%

Borrow Fee

105.50%

↓ 29.3%

Available Shares

300K

↑ 3.9%

Price Chart

Company Overview

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001659617

Asset Type: CS

Market Data

Market Cap: $14,977,800

Employees: 17

Status: Active

Short Interest

Current Borrow Fee 105.50%

Range: 102.64% - 105.75%

Available Shares 300K

Range: 100K - 300K

Recent Changes

Fee Change: ↑ 1.3%

Available Change: ↑ 100.0%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime